Tag: Swiss pharmaceutics innovator

This per-share takeover price is significantly higher than the German manufacturer’s going market performance. At the final bell on Monday, MorphoSys’s Nasdaq shares priced at $17.27. Bloomberg claimed that this acquisition was an attempt by Vasant Narasimhan, the Novartis CEO, to prove to investors that he could drive financial and organisational growth.  After disappointing financial…